Neurotoxicity of methamphetamine

Handbook of Neurotoxicity

Volumn 3, Issue , 2014, Pages 2207-2230

  Moratalla, Rosario ^a   Ares Santos, Sara ^a   Granado, Noelia ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Amphetamine derivatives; Designer drugs; Dopamine; Drug addiction; Methamphetamine; Neurotoxicity; Parkinson's disease; Psychomotor stimulants

Indexed keywords

EID: 84891874792     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5836-4_123     Document Type: Chapter

References (65)

1. Albers, D. S., & Sonsalla, P. K. (1995). Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: Pharmacological profile of protective and nonprotective agents. The Journal of Pharmacology and Experimental Therapeutics, 275, 1104-1114. http://www. ncbi.nlm.nih.gov/pubmed/8531070.
2. Ares-Santos, S., Granado, N., Oliva, I., O'Shea, E., Martin, E. D., Colado, M. I., & Moratalla, R. (2012). Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphet- amine. Neurobiology of Disease, 45(2), 810-820. http://www.ncbi.nlm.nih.gov/pubmed/ 22115942.
3. Ares-Santos S, Granado N, Moratalla R. (2013). The role of dopamine receptors in the neurotoxicity of methamphetamine. Journal of Internal Medicine, 273, 437-453.
4. Asanuma, M., Hayashi, T., Ordonez, S. V., Ogawa, N., & Cadet, J. L. (2000). Direct interactions of methamphetamine with the nucleus. Brain Research. Molecular Brain Research, 80(2), 237-243. http://www.ncbi.nlm.nih.gov/pubmed/11038257
5. Bourque, M., Bin Liu, Dluzen, D. E., & Di Paolo, T. (2007). Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity. Biochemical Pharmacology, 74(9), 1413-1423. http://www.ncbi.nlm.nih.gov/pubmed/17825264.
6. Bowyer, J. F., Davies, D. L., Schmued, L., Broening, H. W., Newport, G. D., Slikker, W., & Holson, R. R. (1994). Further studies of the role of hyperthermia in methamphetamine neurotoxicity. The Journal of Pharmacology and Experimental Therapeutics, 268(3), 1571-1580. http://www.ncbi.nlm.nih.gov/pubmed/8138969.
7. Brown, J. M., Quinton, M. S., & Yamamoto, B. K. (2005). Methamphetamine-induced inhibition of mitochondrial complex II: Roles of glutamate and peroxynitrite. Journal of Neurochemistry, 95(2), 429-436. http://www.ncbi.nlm.nih.gov/pubmed/16086684.
8. Butterfield, D. A, Reed, T., & Sultana, R. (2011). Roles of 3-nitrotyrosine- and 4-hydroxynonenal- modified brain proteins in the progression and pathogenesis of Alzheimer's disease. Free Radical Research, 45(1), 59-72. http://www.ncbi.nlm.nih.gov/pubmed/20942567.
9. Cadet, J. L., & Krasnova, I. N. (2009). Molecular bases of methamphetamine-induced neurodegeneration. International Review of Neurobiology, 88, 101-119. (1st ed.). Elsevier. http://www.ncbi.nlm.nih.gov/pubmed/19897076.
10. Chan, P., Di Monte, D. A., Luo, J. J., DeLanney, L. E., Irwin, I., & Langston, J. W. (1994). Rapid ATP loss caused by methamphetamine in the mouse striatum: Relationship between energy impairment and dopaminergic neurotoxicity. Journal of Neurochemistry, 62(6), 2484-2487. http://www.ncbi.nlm.nih.gov/pubmed/8189253.
11. Chen, J., Rusnak, M., Luedtke, R. J., & Sidhu, A. (2004). D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. The Journal of Biological Chemistry, 279(38), 39317-3930. http://www.ncbi.nlm.nih.gov/pubmed/15247297.
12. Chen, P.-C., Vargas, M. R., Pani, A. K., Smeyne, R. J., Johnson, D. A., Yuet Wai Kan, & Johnson, J. A. (2009). Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proceedings of the National Academy of Sciences of the United States of America, 106(8), 2933-2938. http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=2650368&tool=pmcentrez&rendertype=abstract.
13. Clark, J., & Simon, D. K. (2009). Transcribe to survive: Transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. Antioxidants & Redox Signaling, 11(3), 509-528. http://www.ncbi.nlm.nih.gov/pubmed/18717631.
14. Clark, K. H., Wiley, C. A., & Bradberry, C. W. (2013). Psychostimulant abuse and neuroinflammation: Emerging evidence of their interconnection. Neurotoxicity Research, 23(2), 174-188. http://www.ncbi.nlm.nih.gov/pubmed/22714667.
15. D'Astous, M., Mickley, K. R., Dluzen, D. E., & Di Paolo, T. (2005). Differential protective properties of estradiol and tamoxifen against methamphetamine-induced nigrostriatal dopaminergic toxicity in mice. Neuroendocrinology, 82(2), 111-120. http://www.ncbi.nlm.nih.gov/ pubmed/16446547.
16. Darmopil, S., Martin, A. B., De Diego, I. R., Ares, S., & Moratalla, R. (2009). Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biological Psychiatry, 66(6), 603-613. http://www.ncbi.nlm.nih.gov/pubmed/ 19520364.
17. Degenhardt, L., Baker, A., & Maher, L. (2008). Methamphetamine: Geographic areas and populations at risk, and emerging evidence for effective interventions. Drug and Alcohol Review, 27(3), 217-219. http://www.ncbi.nlm.nih.gov/pubmed/18368601.
18. Deng, X., & Cadet, J. L. (2000). Methamphetamine-induced apoptosis is attenuated in the striata of copper-zinc superoxide dismutase transgenic mice. Brain Research. Molecular Brain Research, 83(1-2), 121-124. http://www.ncbi.nlm.nih.gov/pubmed/11072101.
19. Dluzen, D. E. (2004). The effect of gender and the neurotrophin, BDNF, upon methamphetamine- induced neurotoxicity of the nigrostriatal dopaminergic system in mice. Neuroscience letters, 359(3), 135-138. http://www.ncbi.nlm.nih.gov/pubmed/15050682.
20. Eisch, A. J., & Marshall, J. F. (1998). Methamphetamine neurotoxicity: Dissociation of striatal dopamine terminal damage from parietal cortical cell body injury. Synapse (New York, N.Y.), 30(4), 433-445. http://www.ncbi.nlm.nih.gov/pubmed/9826235.
21. Eyerman, D. J., & Yamamoto, B. K. (2005). Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum. The Journal of Pharmacology and Experimental Therapeutics, 312(1), 160-169. http://www.ncbi.nlm.nih.gov/pubmed/15331654.
22. Fleckenstein, A. E., Metzger, R. R., Beyeler, M. L., Gibb, J. W., & Hanson, G. R. (1997). Oxygen radicals diminish dopamine transporter function in rat striatum. European Journal of Pharmacology, 334(1), 111-114. http://www.ncbi.nlm.nih.gov/pubmed/9346337.
23. Fumagalli, F., Gainetdinov, R. R., Valenzano, K. J., & Caron, M. G. (1998). Role of dopamine transporter in methamphetamine-induced neurotoxicity: Evidence from mice lacking the transporter. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 18(13), 4861-4869. http://www.ncbi.nlm.nih.gov/pubmed/9634552.
24. Granado, N., O'Shea, E., Bove, J., Vila, M., Colado, M. I., & Moratalla, R. (2008a). Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. Journal of Neurochemistry, 107(4), 1102-1112. http://www.ncbi.nlm.nih.gov/pubmed/ 18823368.
25. Granado, N., Ortiz, O., Suarez, L. M., Martin, E. D., Ceha, V., Solis, J. M., & Moratalla, R. (2008b). D1 but not D5 dopamine receptors are critical for LTP, spatial learning, and LTP- Induced arc and zif268 expression in the hippocampus. Cerebral Cortex (New York, N.Y.: 1991), 18(1), 1-12. http://www.ncbi.nlm.nih.gov/pubmed/17395606.
26. Granado, N., Ares-Santos, S., O'Shea, E., Vicario-Abejon, C., Colado, M. I., & Moratalla, R. (2010). Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration: Early loss of TH in striosomes after methamphet- amine. Neurotoxicity Research, 18(1), 48-58. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2875475&tool=pmcentrez&rendertype=abstract.
27. Granado, N., Ares-Santos, S., Oliva, I., O'Shea, E., Martin, E. D., Colado, M. I., & Moratalla, R. (2011a). Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiology of Disease, 42(3), 391-403. http://www.ncbi.nlm.nih.gov/pubmed/21303698.
28. Granado, N., Lastres-Becker, I., Ares-Santos, S., Oliva, I., Martin, E., Cuadrado, A., & Moratalla, R. (2011b). Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum. Glia, 59(12), 1850-1863. http://www.ncbi.nlm.nih. gov/pubmed/21882243.
29. Hirata, H., Ladenheim, B., Carlson, E., Epstein, C., & Lud, J. (1996). Dopaminergic loss in mouse brain: Attenuation in CuZn-superoxide dismutase transgenic mice. Brain Res, 714, 95-103.
30. Hirata, H., Asanuma, M., & Cadet, J. L. (1998). Superoxide radicals are mediators of the effects of methamphetamine on Zif268 (Egr-1, NGFI-A) in the brain: Evidence from using CuZn superoxide dismutase transgenic mice. Brain Research. Molecular Brain Research, 58(1-2), 209-216. http://www.ncbi.nlm.nih.gov/pubmed/9685645
31. Hurtig, H. I., Trojanowski, J. Q., Galvin, J., Ewbank, D., Schmidt, M. L., Lee, V. M., Clark, C. M., Glosser, G., Stern, M. B., Gollomp, S. M., & Arnold, S. E. (2000). Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology, 54(10), 1916-1921. http://www.ncbi.nlm.nih.gov/pubmed/10822429.
32. Itzhak, Y., Gandia, C., Huang, P. L., & Ali, S. F. (1998). Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity. The Journal of Pharmacology and Experimental Therapeutics, 284(3), 1040-1047. http:// www.ncbi.nlm.nih.gov/pubmed/9495865
33. Itzhak, Y., Martin, J. L., & Ali, S. F. (2002). Methamphetamine-induced dopaminergic neurotoxicity in mice: Long-lasting sensitization to the locomotor stimulation and desensitization to the rewarding effects of methamphetamine. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 26(6), 1177-1183. http://www.ncbi.nlm.nih.gov/pubmed/12452543.
34. Jayanthi, S., Ladenheim, B., & Cadet, J. L. (1998). Methamphetamine-induced changes in antioxidant enzymes and lipid peroxidation in copper/zinc-superoxide dismutase transgenic mice. Annals of the New York Academy of Sciences, 844, 92-102. http://www.ncbi.nlm.nih. gov/pubmed/9668667.
35. Jayanthi, S., McCoy, M. T., Beauvais, G., Ladenheim, B., Gilmore, K., Wood, W., Becker, K., & Cadet, J. L. (2009). Methamphetamine induces dopamine D1 receptor-dependent endoplasmi- creticulum stress-related molecular events in the rat striatum. PloS One, 4(6), e6092. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2699544&tool=pmcentrez&render type=abstract.
36. Jayanthi, S., Xiaolin Deng, Ladenheim, B., McCoy, M. T., Cluster, A., Ning-Sheng Cai, & Cadet, J. L. (2005). Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 102(3), 868-873. http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=545515&tool=pmcentrez&rendertype=abstract.
37. Jeng, W., Ramkissoon, A., Parman, T., & Wells, P. G. (2006). Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal degeneration. FASEB Journal: official publication of the Federation of American Societies for Experimental Biology, 20(6), 638-650. http://www. ncbi.nlm.nih.gov/pubmed/16581972.
38. Johnson, J. A., Johnson, D. A., Kraft, A. D., Calkins, M. J., Jakel, R. J., Vargas, M. R., & Pei-Chun Chen. (2008). The Nrf2-ARE pathway: An indicator and modulator of oxidative stress in neurodegeneration. Annals of the New York Academy of Sciences, 1147, 61-69. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2605641&tool=pmcentrez&render type=abstract.
39. Krasnova, I.N., & Cadet, J. L. (2009). Methamphetamine toxicity and messengers of death. Brain Research Reviews, 60(2), 379-407. http://dx.doi.org/10.1016/j.brainresrev.2009.03.002.
40. Larsen, K. E., Fon, E. A., Hastings, T. G., Edwards, R. H., & Sulzer, D. (2002). Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 22(20), 8951-8960. http://www.ncbi.nlm.nih.gov/ pubmed/12388602
41. LaVoie, M. J., & Hastings, T. G. (1999). Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: Evidence against a role for extracellular dopamine. The Journal ofNeuroscience: The Official Journal ofthe Society for Neuroscience, 19(4), 1484-1491. http://www.ncbi.nlm.nih.gov/pubmed/9952424.
42. Li, Yan-hong, Hui-jun Wang, & Dong-fang Qiao. (2008). Effect of methamphetamine on the microglial cells and activity of nitric oxide synthases in rat striatum. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 28(10), 1789-1791. http://www.ncbi. nlm.nih.gov/pubmed/18971173.
43. Lo, Shih-Ching, Xuchu Li, Henzl, M. T., Beamer, L. J., & Hannink, M. (2006). Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. The EMBO Journal, 25(15), 3605-3617. http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=1538563&tool=pmcentrez&rendertype=abstract.
44. Matsuzaki, H., Namikawa, K., Kiyama, H., Mori, N., & Sato, K. (2004). Brain-derived neurotrophic factor rescues neuronal death induced by methamphetamine. Biological Psychiatry, 55(1), 52-60. http://www.ncbi.nlm.nih.gov/pubmed/14706425.
45. McCann, U. D., Wong, D. F., Yokoi, F., Villemagne, V., Dannals, R. F., & Ricaurte, G. A. (1998). Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [11C] WIN-35, 428. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 18(20), 8417-8422. http://www.ncbi.nlm.nih.gov/pubmed/9763484
46. Medina, L., Figueredo-Cardenas, G., & Reiner, A. (1996). Differential abundance of superoxide dismutase in interneurons versus projection neurons and in matrix versus striosome neurons in monkey striatum. Brain Research, 708(1-2), 59-70. http://www.ncbi.nlm.nih.gov/pubmed/ 8720860
47. Melega, W. P., Lacan, G., Desalles, A. A., & Phelps, M. E. (2000). Long-term methamphetamine- induced decreases of [(11)C]WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey. Synapse (New York, N.Y.), 35(4), 243-249. http://www.ncbi.nlm. nih.gov/pubmed/10657033.
48. Miller, D. B., & O'Callaghan, J. P. (2003). Elevated environmental temperature and methamphet- amine neurotoxicity. Environmental Research, 92(1), 48-53. http://www.ncbi.nlm.nih.gov/ pubmed/12706754.
49. Nash, J. F., & Yamamoto, B. K. (1992). Methamphetamine neurotoxicity and striatal glutamate release: Comparison to 3,4-methylenedioxymethamphetamine. Brain Research, 581(2), 237-243. http://www.ncbi.nlm.nih.gov/pubmed/1356579.
50. O'Callaghan, J. P., & Miller, D. B. (1994). Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. The Journal of Pharmacology and Experimental Therapeutics, 270(2), 741-751. http://www.ncbi.nlm.nih.gov/pubmed/8071867.
51. Ortiz, O., Delgado-Garcia, J. M., Espadas, I., Bahi, A., Trullas, R., Dreyer, J. L., Gruart, A., & Moratalla, R. (2010). Associative learning and CA3-CA1 synaptic plasticity are impaired in D1R null, Drd1a-/- mice and in hippocampal siRNA silenced Drd1a mice. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 30(37), 12288-12300. http://www.ncbi.nlm.nih.gov/pubmed/20844125.
52. Rangasamy, T., Chung Y. Cho, Thimmulappa, R. K., Lijie Zhen, Sorachai S. Srisuma, Kensler, T. W., Masayuki Yamamoto, Petrache, I., Tuder, R. M., & Biswal, S. (2004). Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. The Journal of Clinical Investigation, 114(9), 1248-1259. http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=524225&tool=pmcentrez&rendertype=abstract.
53. Sattler, R., & Tymianski, M. (2000). Molecular mechanisms of calcium-dependent excitotoxicity. Journal of Molecular Medicine (Berlin, Germany), 78(1), 3-13. http://www.ncbi.nlm.nih.gov/ pubmed/10759025
54. Sonsalla, P. K., Gibb, J. W., & Hanson, G. R. (1986). Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. The Journal of Pharmacology and Experimental Therapeutics, 238(3), 932-937. http://www.ncbi. nlm.nih.gov/pubmed/2943891.
55. Sonsalla, P. K., Nicklas, W. J., & Heikkila, R. E. (1989). Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science (New York, N.Y.), 243(4889), 398-400. http://www.ncbi.nlm.nih.gov/pubmed/2563176.
56. Sriram, K., Miller, D. B., & O'Callaghan, J. P. (2006). Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: Role of tumor necrosis factor-alpha. Journal of Neurochemistry, 96(3), 706-718. http://www.ncbi.nlm.nih.gov/ pubmed/16405514.
57. Sulzer, D., Sonders, M. S., Poulsen, N. W., & Galli, A. (2005). Mechanisms of neurotransmitter release by amphetamines: A review. Progress in Neurobiology, 75(6), 406-33. http://www. ncbi.nlm.nih.gov/pubmed/15955613.
58. Thomas, D. M., Francescutti-Verbeem, D. M., & Kuhn, D. M. (2008). The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. Journal of Neurochemistry, 105(3), 605-616. http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=2668123&tool=pmcentrez&rendertype=abstract.
59. UNODC. (2012). World drug report 2012. United Nations publication, Sales No. E.12.XI.1.
60. Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Franceschi, D., Sedler, M., Gatley, S. J., Miller, E., Hitzemann, R., Ding, Y. S., & Logan, J. (2001a). Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 21(23), 9414-9418. http://www.ncbi.nlm.nih.gov/pubmed/11717374
61. Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Leonido-Yee, M., Franceschi, D., Sedler, M. J., Gatley, S. J., Hitzemann, R., Ding, Y. S., Logan, J., Wong, C., & Miller, E. N. (2001b). Association of dopamine transporter reduction with psychomotor impairment in methamphet- amine abusers. The American Journal of Psychiatry, 158(3), 377-382. http://www.ncbi.nlm. nih.gov/pubmed/11229977.
62. Wagner, G. C., Carelli, R. M., & Jarvis, M. F. (1986). Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1-methyl-4-phenyl pyridinium ion. Neuropharmacology, 25(5), 559-561. http://www.ncbi.nlm.nih.gov/pubmed/3488515.
63. White, N. M., & Hiroi, N. (1998). Preferential localization of self-stimulation sites in striosomes/ patches in the rat striatum. Proceedings of the National Academy of Sciences of the United States of America, 95(11), 6486-6491. http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=27819&tool=pmcentrez&rendertype=abstract
64. Xie, T., McCann, U. D., Kim, S., Yuan, J., & Ricaurte, G. A. (2000). Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: Implications for methamphetamine-induced dopaminergic neurotoxicity. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 20(20), 7838-7845. http://www. ncbi.nlm.nih.gov/pubmed/11027249
65. Yamamoto, B. K., & Zhu, W. (1998). The effects of methamphetamine on the production of free radicals and oxidative stress. The Journal of Pharmacology and Experimental Therapeutics, 287(1), 107-114. http://www.ncbi.nlm.nih.gov/pubmed/9765328.